Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
ANCA-associated vasculitis
KDIGO
glomerular diseases
glomerulonephritis
guideline
systematic review
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
11
09
2023
revised:
20
10
2023
accepted:
20
10
2023
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
22
2
2024
Statut:
ppublish
Résumé
In 2021, the Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases was published. KDIGO is committed to providing the nephrology community with periodic updates, based on new developments for each disease. For patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), avacopan received regulatory approval in late 2021, leading to this KDIGO guideline update. In addition, the evidence supporting a lower-dose glucocorticoid induction regimen or even complete replacement of glucocorticoids has become stronger. Herein, an executive summary of the most important guideline changes from the AAV chapter is provided as a quick reference.
Identifiants
pubmed: 38388147
pii: S0085-2538(23)00745-7
doi: 10.1016/j.kint.2023.10.009
pii:
doi:
Types de publication
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-449Informations de copyright
Copyright © 2023 Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. All rights reserved.